论文部分内容阅读
目的:探讨培美曲塞与顺铂联合治疗晚期食道癌的临床应用价值。方法:选择2013年1月-12月我院收治的患有晚期食道癌的病人72例,将其分成对照组与研究组,每组各36例,对照组采用5-氟尿嘧啶联合顺铂进行治疗,研究组给予培美曲塞联合顺铂,比较分析两组临床疗效。结果:经治疗,研究组的治疗总有效率为97.2%,显著高于对照组(P<0.05)。研究组患者的恶心与呕吐、便秘、白细胞降低、贫血等不良发应的发生率均显著低于对照组(P<0.05)。结论:将培美曲塞与顺铂联合运用于晚期食道癌的临床治疗,疗效确切,不良反应小,患者耐受性好,值得临床推广与应用。
Objective: To investigate the clinical value of pemetrexed combined with cisplatin in the treatment of advanced esophageal cancer. Methods: Seventy-two patients with advanced esophageal cancer admitted to our hospital from January to December in 2013 were divided into control group and study group, with 36 cases in each group. The control group was treated with 5-fluorouracil and cisplatin , The study group given pemetrexed combined with cisplatin, comparative analysis of two groups of clinical efficacy. Results: After treatment, the total effective rate of the study group was 97.2%, which was significantly higher than that of the control group (P <0.05). The incidence of nauseous and vomiting, constipation, leukopenia and anemia in study group were significantly lower than those in control group (P <0.05). Conclusion: The combination of pemetrexed and cisplatin in the treatment of advanced esophageal cancer has definite curative effect, small adverse reaction, good patient tolerance, and worthy of clinical promotion and application.